Global Neuromodulation Devices market set to grow at a CAGR of 12.1% to 2030

Thursday 11 June 2020, Amsterdam

ASDReports has launched a new pharma report Global Neuromodulation Devices Report 2020-2030: Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), Other Applications.

Neuromodulation is one of the fastest growing sectors in the medical devices market for the potential it has as being a relatively non-invasive and cost-effective way of treating debilitating illnesses. This potential remains, yet, unexploited. Growing research into new forms of neuromodulation and the ways it can be applied to different illnesses will drive this market. This is because the techniques not only treat the symptoms of illnesses such as chronic pain, but also provides an effective alternative to drug-based medication that might cause severe side-effects or lead to drug dependence.

The lead analyst of the report commented "Ageing populations in both developed and developing countries and the increasing prevalence of age-related conditions and chronic diseases will drive growth in the neuromodulation devices market. Emerging economies such as China and India will see their neuromodulation devices market increase at a rapid rate during the second half of the forecasted period, due to increased development and research."

Leading companies featured in the report include Medtronic , Boston Scientific , Abbott Laboratories , LivaNova PLC , Stryker Corporation , Nevro Corp. & Other Companies